mAbTree Biologics Partners with Shilpa Biologicals for Next-Gen Checkpoint Inhibitor

• mAbTree Biologics AG has partnered with Shilpa Biologicals Pvt Ltd to co-develop and commercialize a novel checkpoint inhibitor for immuno-oncology.

• Shilpa Biologicals will support clinical development, GMP manufacturing, and commercial supply, leveraging its R&D and biomanufacturing capabilities.

mAbTree Biologics AG has entered an exclusive co-development and commercialization partnership with Shilpa Biologicals Pvt Ltd, a subsidiary of Shilpa Medicare Limited, for its novel checkpoint inhibitor. The collaboration aims to advance immunotherapy with a next-generation biologic designed to enhance T cell activation and improve immune responses against tumors.

Under the agreement, Shilpa Biologicals will provide end-to-end development support, including clinical studies and long-term GMP manufacturing. Additionally, the company will facilitate mAbTree’s access to India and other global markets through its partner network. The novel monoclonal antibody targets an immune checkpoint protein distinct from the established PD-1/PD-L1 blockade, with potential applications across multiple cancer types, including lung cancer and hematologic malignancies.

Shilpa Biologicals plans to utilize its biomanufacturing facility in Dharwad, Karnataka, and extensive R&D capabilities to advance the therapy’s development. Commenting on the partnership, Dr. Sridevi Khambhampaty, CEO of Shilpa Biologicals, stated, “This novel therapy represents a new frontier in immuno-oncology, with the potential to expand treatment options for patients who do not benefit from current immunotherapies.”

Raj Andhuvan, CEO of mAbTree Biologics, emphasized the significance of the collaboration, highlighting Shilpa’s expertise in biomanufacturing and market access. He stated that the partnership would enable greater access to innovative medicines, particularly in India and other regions with limited therapeutic options.

The agreement reflects both companies’ commitment to expanding treatment options in oncology, leveraging strategic partnerships to accelerate drug development and commercialisation in the immunotherapy space.